Saturday 17 October 2026
Export VCYT’s income statement to Excel — free account
Veracyte, Inc.
VCYT Healthcare Diagnostics & Research
Veracyte, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $517.1 million, up 16.0% from fiscal 2024. In the quarter to June 2026, revenue grew 15.5%, EPS grew 3,300.0% and free cash flow grew 33.0%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three.
43.12
1.27
−2.86%
Follow VCYT
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
40.78 | 29.02 | 50.12 | 88.03 |
+8 more quarters Free account |
P/S ratio |
8.36 | 4.73 | 6.40 | 5.46 | |
P/FCF ratio |
28.30 | 16.49 | 26.13 | 27.52 | |
P/Operating CF |
102.49 | 72.75 | 62.92 | 60.38 | |
P/B ratio |
3.38 | 1.91 | 2.53 | 2.15 | |
Price to Tangible BV |
8.72 | 5.21 | 7.30 | 6.79 | |
EV/Sales |
7.50 | 3.92 | 5.60 | 4.72 | |
EV/EBITDA |
34.00 | 22.14 | 38.17 | 52.96 | |
EV/Operating CF |
23.62 | 12.79 | 21.26 | 21.60 | |
EV/FCF |
25.39 | 13.68 | 22.88 | 23.81 | |
Quick Ratio |
8.60 | 8.72 | 7.63 | 5.74 | |
Current Ratio |
9.16 | 9.31 | 8.15 | 6.23 | |
Net Debt/EBITDA |
(17.91) | (15.99) | (9.87) | (13.31) | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.40 | 0.39 | 0.38 | 0.37 | |
Operating CF/Net income |
1.80 | 1.23 | 1.28 | 2.34 | |
Capex/Depreciation |
(0.69) | (0.61) | (0.81) | (0.61) | |
Research and Development Expense of Revenue |
19.59% | 19.49% | 14.82% | 12.12% | |
Selling, General and Administrative Expense of Revenue |
37.06% | 36.55% | 30.79% | 39.23% | |
Intangible Assets out of Total Assets |
0.57 | 0.59 | 0.61 | 0.63 | |
Share Based Compensation of Revenue |
9.37% | 9.18% | 7.75% | 8.16% | |
Graham Net Nets |
0.10 | 0.17 | 0.12 | 0.13 | |
Graham Number |
23.72 | 20.55 | 17.75 | 11.84 | |
Earnings Yield |
2.45% | 3.45% | 2.00% | 1.14% | |
Free Cash Flow Yield |
3.53% | 6.06% | 3.83% | 3.63% | |
Revenue per Share |
1.88 | 1.75 | 1.79 | 1.68 | |
Operating CF per Share |
0.57 | 0.44 | 0.67 | 0.57 | |
Capex per Share |
(0.04) | (0.04) | (0.05) | (0.04) | |
Free Cash Flow per Share |
0.54 | 0.41 | 0.62 | 0.53 | |
Cash per Share |
6.07 | 5.52 | 5.25 | 4.65 | |
Shareholders Equity per Share |
17.36 | 16.90 | 16.66 | 15.98 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
17.36 | 16.90 | 16.66 | 15.98 | |
Free Cash Flow |
42.97 | 32.25 | 48.80 | 41.97 | |
Working Capital |
512.04 | 466.06 | 428.44 | 377.07 | |
Capital Expenditures |
(2.86) | (2.96) | (3.78) | (2.79) | |
Net Current Asset Value |
476.81 | 430.18 | 391.93 | 339.10 | |
EV/EBIT |
39.84 | 27.41 | 50.15 | 94.46 | |
Capex to Sales |
0.02 | 0.02 | 0.03 | 0.02 | |
Price to Operating Income |
44.41 | 33.05 | 57.26 | 109.17 | |
| Other line items | |||||
Average Receivables |
52.50 | 51.95 | 45.59 | 48.32 | |
Average Payables |
9.74 | 11.31 | 6.61 | 7.59 | |
Average Inventory |
23.84 | 22.84 | 21.15 | 20.35 | |
Average Assets |
1,415.24 | 1,375.91 | 1,353.03 | 1,321.40 | |
Average Common Equity |
1,304.73 | 1,269.67 | 1,242.77 | 1,216.85 |
Columns are period end dates